HUTCHMED to Host Expert Briefing on Latest Clinical Data for Savolitinib in NSCLC

Stock News08:10

HUTCHMED (00013) has announced that it will jointly hold an online expert briefing for analysts and investors with Citigroup Global Markets Asia Limited (Citigroup) to discuss the latest Phase III clinical data for savolitinib in the treatment of MET-driven non-small cell lung cancer, recently presented at the 2026 European Society for Medical Oncology (ESMO) Annual Meeting.

The online meeting will be held on Thursday, November 5, 2026, at 4:30 p.m. Hong Kong time / 8:30 a.m. Greenwich Mean Time / 3:30 a.m. U.S. Eastern Time.

Professor Wu Yilong, the principal investigator of the SANOVO study, will serve as the keynote speaker, sharing professional insights on the latest clinical data and treatment strategies for MET-driven non-small cell lung cancer.

Dr. Su Weiguo, Chief Executive Officer (currently on leave) and Chief Scientific Officer of HUTCHMED, will also participate in the panel discussion, combining data from the SANOVO China study and the SAFFRON global study to provide an in-depth exploration of savolitinib's development progress and global regulatory registration prospects.

The meeting will be moderated by Mr. Peng Yingqi, Asia Healthcare Research Analyst at Citigroup.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment